Press releases

The Swedish Economic Crime Authority terminates the investigation of Oncopeptide's Chief Scientific Officer Jakob Lindberg

May 30, 2023

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, has been informe...

Read more

Bulletin from the Annual General Meeting in Oncopeptides AB (publ)

Regulatory

May 25, 2023

Stockholm, Sweden – The Annual General Meeting in Oncopeptides AB (publ) (ONCO) was held on Thursday, 25 May 2023. At the Annual General Meeting, the following principal resolutions were passed

Read more

Correction: Oncopeptides presents new data at the European Haematology Association meeting

May 12, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...

Read more

Oncopeptides presents new data at the European Haematology Association meeting

May 11, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...

Read more

Oncopeptides publishes Q1 report 2023

Regulatory

May 4, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today publishes t...

Read more

Oncopeptides issues warrants to utilize the first loan tranche from EIB

Regulatory

May 3, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat haematological diseases, today announced ...

Read more

Invitation to presentation of the Q1 report 2023

May 2, 2023

Oncopeptides AB (publ) a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, will publish the report for the first quart...

Read more

Oncopeptides publishes the 2022 Annual Report

Regulatory

April 25, 2023

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announces t...

Read more

Annual General Meeting in Oncopeptides AB (publ)

Regulatory

April 21, 2023

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Annua...

Read more

Oncopeptides presents new scientific data at European Myeloma Network Meeting

April 20, 2023

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development, and commercialization of therapies for difficult-to-treat hematological diseases, today announced ...

Read more

Oncopeptides receives a research grant from Sweden´s Innovation Agency to explore the PDC platform in solid tumors

March 28, 2023

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, today announced t...

Read more

Oncopeptides CSO released from custody

Regulatory

March 10, 2023

Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, has been info...

Read more

Oncopeptides CSO investigated for violation of the Market Abuse Act

Regulatory

March 8, 2023

Oncopeptides AB (publ), has been informed by the Swedish Economic Crime Authority that the CSO Jakob Lindberg has been arrested for a suspected violation of the Market Abuse Act (Sw. lag om straff för...

Read more

Oncopeptides publishes year-end report 2022

Regulatory

February 16, 2023

Oncopeptides AB (publ), a biotech company focused on research, development and commercialization of therapies for difficult-to-treat hematological diseases, has today published the year-end report 202...

Read more

Invitation to presentation of the year-end report 2022

February 9, 2023

Oncopeptides AB (publ) a biotech company focused on the commercialization, research and development of therapies for difficult-to-treat hematological diseases, will publish the report for the fourth q...

Read more

Oncopeptides Chief Financial Officer Holger Lembrer takes office today

Regulatory

January 18, 2023

STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematolog...

Read more

Oncopeptides appoints Holger Lembrer as Chief Financial Officer

Regulatory

January 11, 2023

STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today...

Read more

Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer

Regulatory

January 4, 2023

STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today ...

Read more